CMP vs Fascia Iliaca Block

Loyola University40 enrolled

Overview

Complete motorsparing protocol (CMP) has been developed to try to minimize the motor nerve block that is created when using Facia iliaca nerve block. The blocks performed in the (CMP) are the cluneal nerve block, Pericapsular nerve group block and lateral femoral cutaneous block. On the clinical trial, the investigators will randomize the participants that meet criteria to CMP or Fascia iliaca Block and compare the amount of opioid needed post op during 24 hours and their pain scores.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pain, Postoperative Hip Arthroplasty

Interventions

CMPDRUG

Cluneal nerve Block 0.25% bupivacaine 20ml Pericapsular Nerve group block 0.25% Bupivacaine 20ml Lateral femoral cutaneous Block 0.25% bupivacaine 10ml

Fascia IllicaDRUG

Fascia iliaca block suprainguinal technique 0.25% bupivacaine 50ml

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients ≥ 18 years old * Patients undergoing total hip arthroplasty posterior approach. * Patients willing to participate and sign informed consent Exclusion Criteria: * Severe COPD/other contraindication to general anesthesia that spinal would be more suitable. * Patient with a weight of less than 41 kg * Dementia, not alert or Oriented to person, place, or time * Chronic pain patient with daily opioid use at home. * Patient with allergy to local anesthetics * Patient refusal * Total hip arthroplasty revision * Concomitant pain in different area from operative site. * Pregnancy * Patient with active infection on the injection sites for the blocks * Patients unable or willing to understand or comply with the study protocol

Locations (1)

Loyola University Medical Center

Maywood, Illinois, United States

RECRUITING

Outcomes

Primary Outcomes

Measurement of opioid use

Measurement of opioid use (mg) for pain control after surgery once patient in recovery area

Time frame: 24 hours

Secondary Outcomes

Measurement of the pain control

Measurement of the pain control via numeric rating scale 0-10 where 0 is no pain and 10 is the worst pain.

Time frame: 24 hours

Central Contacts

Carlos Martinez Parra, MD

CONTACT

(708) 216-6462 carlos.martinezparra@lumc.edu

Michael Majewski, MD

CONTACT

(708) 216-6462 mimajewski@lumc.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.